Novo Nordisk to invest DKK1bn in new plant

Published: 22-Jun-2011
Manufacturing Packaging Finance Pharmaceutical

For the production of haemophilia and growth hormone biopharmaceuticals in Kalundborg, Denmark

Danish pharmaceutical company Novo Nordisk is investing close to DKK1bn (€134m) in a new biopharmaceuticals factory in Kalundborg, Denmark.

The factory is expected to create 120–150 new jobs in Kalundborg over the next three years, the company said.

It will produce haemophilia drugs, growth hormone and other medicines.

‘We need to expand our production capacity to meet the future demand for our existing products, but also to be ready to produce future haemophilia products that are in the pipeline,’ said Per Valstorp, senior vice president, Product Supply, Novo Nordisk.

The new factory will cover formulation, freeze-drying, filling and packaging of NovoSeven haemophilia medicine, Norditropin growth hormone and the glucagon product GlucaGen.

Groundbreaking for the new factory will take place on 22 August.

‘We already have similar production in Gentofte, Denmark, and have built up great expertise in the production of biopharmaceuticals in Denmark. We were therefore never in doubt that this new factory should be placed in Denmark,’ added Valstorp.

The packaging facility is expected to be operational in 2013 and the other facilities in 2015.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Read more
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Regulatory

Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA

The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
Manufacturing

Novo Nordisk teams up with Bio Farma and Indonesian government to enhance national diabetes drug accessibility

The collaboration will aim to enhance the availability of insulin and other diabetes drug products in Indonesia, where diabetes is one of the top three killers annually
Distribution

Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride

The two companies aim to expand the distribution of benzalkonium chloride within Europe
Subscribe now